Clinical-stage biopharmaceutical firm, Cellular Biomedicine (CBMG), has established a research collaboration with GE Healthcare Life Sciences China to develop industrial control processes in Chimeric Antigen Receptor T-cell (CAR-T) and stem cell manufacturing.
A joint laboratory within CBMG’s new Shanghai Zhangjiang GMP-facility will be established and dedicated to the development of a functionally integrated and automated immunotherapy cell preparation system.
The two companies plan to develop automated CAR-T and stem cell manufacturing capabilities that build upon the accreditation of CBMG’s GMP facilities in Shanghai, Wuxi and Beijing.
Cellular Biomedicine's GMP facilities in China consist of twelve independent cell production lines, designed and managed according to both China and US GMP standards.
CBMG's new Zhangjiang facility and Beijing GMP-facilities will have a combined 70,000 square feet for development and production.
